Nawal Abdullah Murtadha (1)
General Background: Alzheimer’s disease is a progressive neurodegenerative disorder in which cognitive decline is closely linked to blood–brain barrier dysfunction. Specific Background: Tight-junction proteins such as Claudin-5 and Angulin-1 play key roles in maintaining barrier integrity, yet their involvement in Alzheimer’s pathology remains insufficiently clarified, and evidence on associated micronutrient alterations is still limited. Knowledge Gap: Despite emerging data suggesting barrier disruption and B-vitamin deficiencies in Alzheimer’s disease, the combined diagnostic relevance of Claudin-5, Angulin-1, and vitamins B9 and B12 has not been systematically examined. Aims: This study investigates the relationship between Claudin-5 and Angulin-1 in Alzheimer’s disease and evaluates differences in serum vitamin B9 and B12 levels between affected individuals and healthy controls. Results: Serum analyses revealed significantly reduced Angulin-1, Claudin-5, vitamin B9, and vitamin B12 levels in Alzheimer’s patients, alongside marked alterations in lipid profiles. ROC analysis demonstrated exceptionally high diagnostic performance for all measured biomarkers. Novelty: This work provides integrated biochemical evidence linking tight-junction protein depletion with B-vitamin deficiencies in Alzheimer’s disease, suggesting a coordinated disruption of vascular and metabolic pathways. Implications: The identified biomarkers show strong potential for non-invasive diagnostic applications and may guide the development of therapeutic strategies aimed at restoring barrier integrity and micronutrient balance.Highlight :
Claudin-5 and Angulin-1 show significant reductions in Alzheimer’s patients, reflecting impaired tight-junction function in the blood–brain barrier.
Vitamin B9 and B12 levels are markedly lower in Alzheimer’s patients than in healthy controls, indicating an important metabolic alteration.
All biomarkers demonstrate high diagnostic performance, with strong sensitivity and specificity based on ROC analysis.
Keywords : Claudin-5, Angulin-1, Alzheimer’s disease, Vitamin B9, Vitamin B12
S. Gauthier, C. Webster, S. Servaes, J. Morais, and P. Rosa-Neto, World Alzheimer Report 2022: Life After Diagnosis: Navigating Treatment, Care and Support. London, UK: Alzheimer’s Disease International, 2022.
S. Hameed et al., “Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and Its Clinical Implication in the Management of Alzheimer’s Disease,” J. Alzheimer’s Dis. Rep., vol. 4, pp. 21–37, 2020.
J. Cummings et al., “Alzheimer’s Disease Drug Development Pipeline: 2022,” Alzheimer’s Dement., vol. 8, p. e12295, 2022.
S. Tsukita, H. Tanaka, and A. Tamura, “The Claudins: From Tight Junctions to Biological Systems,” Trends Biochem. Sci., vol. 44, pp. 141–152, 2019.
T. Nitta et al., “Size-Selective Loosening of the Blood–Brain Barrier in Claudin-5-Deficient Mice,” J. Cell Biol., vol. 161, pp. 653–660, 2003.
Y. Hashimoto et al., “Claudin-5-Binders Enhance Permeation of Solutes Across the Blood–Brain Barrier in a Mammalian Model,” J. Pharmacol. Exp. Ther., vol. 363, pp. 275–283, 2017.
D. Ferguson et al., “Angulin-1/LSR Inhibition Transiently Disrupts the Blood–Tumor Barrier to Enhance Doxil Permeability and Impair Malignant Glioma Progression,” bioRxiv, pp. 2025–07, 2025.
D. Vignone et al., “Modelling the Human Blood–Brain Barrier in Huntington Disease,” Int. J. Mol. Sci., vol. 23, no. 14, p. 7813, 2022.
A. Kalani et al., “A High Methionine, Low Folate and Vitamin B6/B12 Containing Diet Can Be Associated With Memory Loss by Epigenetic Silencing of Netrin-1,” Neural Regen. Res., vol. 14, no. 7, p. 1247, 2019.
L.-T. Sheng et al., “Association Between Dietary Intakes of B Vitamins in Midlife and Cognitive Impairment in Late-Life: The Singapore Chinese Health Study,” J. Gerontol. A Biol. Sci. Med. Sci., vol. 75, no. 6, pp. 1222–1227, 2019.
R. J. Przybelski and N. C. Binkley, “Is Vitamin D Important for Preserving Cognition? A Positive Correlation of Serum 25-Hydroxyvitamin D Concentration With Cognitive Function,” Arch. Biochem. Biophys., vol. 460, no. 2, pp. 202–205, 2007.
B. V. Zlokovic, “Neurovascular Pathways to Neurodegeneration in Alzheimer’s Disease and Other Disorders,” Nat. Rev. Neurosci., vol. 12, pp. 723–738, 2011.
S. Feng et al., “Matrix Metalloproteinase-2 and -9 Secreted by Leukemic Cells Increase the Permeability of Blood–Brain Barrier by Disrupting Tight Junction Proteins,” PLoS ONE, vol. 6, p. e20599, 2011.
Y. Yang et al., “Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels Is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat,” J. Cereb. Blood Flow Metab., vol. 27, pp. 697–709, 2007.
A. Han et al., “Exploring Neuropsychiatric Manifestations of Vitamin B Complex Deficiencies,” Front. Psychiatry, vol. 16, p. 1569826, 2025.
A. Ahmed et al., “The Role of Vitamins in Dementia Prevention and Cognitive Health: A Comprehensive Review,” J. Alzheimer’s Dis., p. 13872877251379700, 2025.
T. Qian et al., “Association Between Blood Biochemical Factors Contributing to Cognitive Decline and B Vitamins in Patients With Alzheimer’s Disease,” Front. Nutr., vol. 9, p. 823573, 2022.
R. R. Kumar et al., “Role of Vitamins in Neurodegenerative Diseases: A Review,” CNS Neurol. Disord.—Drug Targets, vol. 21, no. 9, pp. 766–773, 2022.
A. Jahan-Mihan et al., “The Role of Water-Soluble Vitamins and Vitamin D in Prevention and Treatment of Depression and Seasonal Affective Disorder in Adults,” Nutrients, vol. 16, no. 12, p. 1902, 2024.
I. G. Zainal, A. A. Safaa, and K. O. Wajeeh, “Comparison of Glyco Proteins Levels With Some Biochemical Parameters in Iraqi Patients With Chronic Liver Diseases,” Innov. J. Med. Health Sci., vol. 2, no. 5, 2012.
S. M. H. Al-Obaidi, S. S. Ahmed, and A. H. A. Al-Obaidi, “Evaluation of Serum Chemerin Level in Non-Diabetic, Hemodialyzed Patients,” Tikrit J. Pharm. Sci., vol. 12, no. 2, pp. 27–35, 2017.
N. Noori and N. Murtadha, “Uncontrolled Type 2 Diabetes Mellitus Modulated Plasma Levels of Lipid Catabolic Proteins,” Georgian Med. News., no. 352–353, pp. 229–233, 2024.
S. F. Shaker, Y. K. Khaleel, and S. D. Khalaf, “Immune Markers, Biochemical Parameters and Genotoxicity in Children Infected With Diabetes Mellitus-Type,” Innov. J. Med. Health Sci., vol. 12, no. 2, pp. 49–53, 2025.
M. I. Habeeb and N. A. Murtadha, “Assessment of Bone Metabolism Markers in Diabetic Patients: Influence of Osteoporosis, Age, and Gender,” Bull. Stomatol. Maxillofac. Surg., 2025, pp. 21–8–204, doi: 10.58240/1829006X.